RE-BVS – Piemonte Repository

Sfoglia per AUTORE
IACOVELLI R
Collezione AOU Novara

Items : 10

Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group? in European urology oncology / Eur Urol Oncol. 2024 Feb;7(1):102-111. doi: 10.1016/j.euo.2023.07.003. Epub 2023 Jul 21.

2024
AOU Novara

Santoni M; Buti S; Myint ZW; Maruzzo M; Iacovelli R; Pichler M; Kopecky J; Kucharz J; Rizzo M; Galli L; Büttner T; De Giorgi U; Kanesvaran R; Fiala O; Grande E; Zucali PA; Kopp RM; Fornarini G; Bourlon MT; Scagliarini S; Molina-Cerrillo J; Aurilio G; Matrana MR; Pichler R; Cattrini C; Büchler T; Massari F; Seront E; Calabrò F; et alii...

Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study. in Cancer immunology, immunotherapy : CII / Cancer Immunol Immunother. 2024 Apr 18;73(6):106. doi: 10.1007/s00262-024-03682-w.

2024
ASL Cuneo 2
AOU Novara

Mosca A; Morelli F; Bisonni R; Bamias A; Santini D; Herchhorn D; Kanesvaran R; Inman E; Caitano M; Messina C; Martignetti A; Kopecky J; Milella M; Procopio G; Abahssain H; Roviello G; Kopp RM; Bassanelli M; Fernandez M; Cutuli HJ; Grillone F; Aceituno LG; Seront E; de Carvalho Fernandes R; Nogueira L; Mennitto A; Dauster B; Monteiro FSM; Barillas A; et alii...

Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1). in Clinical genitourinary cancer / Clin Genitourin Cancer. 2023 Oct;21(5):e309-e319.e1. doi: 10.1016/j.clgc.2023.03.006. Epub 2023 Mar

2023
AOU Novara

Santoni M; Massari F; Myint ZW; Iacovelli R; Pichler M; Basso U; Kopecky J; Kucharz J; Buti S; Salfi A; Büttner T; De Giorgi U; Kanesvaran R; Fiala O; Grande E; Zucali PA; Fornarini G; Bourlon MT; Scagliarini S; Molina-Cerrillo J; Aurilio G; Matrana MR; Pichler R; Cattrini C; Büchler T; Seront E; Calabrò F; Pinto A; Berardi R; et alii...

Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study. in Cancer immunology, immunotherapy : CII / Cancer Immunol Immunother. 2023 Nov;72(11):3665-3682. doi: 10.1007/s00262-023-03518-z. Epub 2023 Sep

2023
AOU Novara

Fiala O; Buti S; Takeshita H; Okada Y; Massari F; Palacios GA; Dionese M; Scagliarini S; Büttner T; Fornarini G; Myint ZW; Galli L; Souza VC; Pichler R; De Giorgi U; Quiroga MNG; Gilbert D; Popovic L; Grande E; Mammone G; Berardi R; Crabb SJ; Molina-Cerrillo J; Freitas M; Luz M; Iacovelli R; Calabrò F; Tural D; Atzori F; et alii...

Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study. in Targeted oncology / Target Oncol. 2023 Jul;18(4):559-570. doi: 10.1007/s11523-023-00978-2. Epub 2023 Jun 27.

2023
AOU Novara

Santoni M; Massari F; Myint ZW; Iacovelli R; Pichler M; Basso U; Kopecky J; Kucharz J; Buti S; Rizzo M; Galli L; Büttner T; De Giorgi U; Kanesvaran R; Fiala O; Grande E; Zucali PA; Fornarini G; Bourlon MT; Scagliarini S; Molina-Cerrillo J; Aurilio G; Matrana MR; Pichler R; Cattrini C; Büchler T; Seront E; Calabrò F; Pinto A; et alii...

Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations. in Minerva urology and nephrology / Minerva Urol Nephrol. 2023 Aug;75(4):460-470. doi: 10.23736/S2724-6051.23.05369-7.

2023
AOU Novara

Porta C; Bamias A; Zakopoulou R; Myint ZW; Cavasin N; Iacovelli R; Pichler M; Kopecky J; Kucharz J; Rizzo M; Galli L; Büttner T; DE Giorgi U; Kanesvaran R; Fiala O; Grande E; Zucali PA; Kopp RM; Fornarini G; Bourlon MT; Scagliarini S; Molina-Cerrillo J; Aurilio G; Matrana MR; Pichler R; Cattrini C; Büchler T; Massari F; Mollica V; et alii...

Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study. in Journal of personalized medicine / J Pers Med. 2022 Apr 30;12(5):727. doi: 10.3390/jpm12050727.

2022
ASL Asti
AOU Novara

Fassan M; Sbaraglia M; Galuppini F; Aberasturi Plata Y; Zito-Marino F; Franco R; Rizzo M; Massari F; Cossarizza A; Bollito E; Salvioni R; Conti G; Lapini A; Colombo P; Patriarca C; Pierconti F; Basso U; Maruzzo M; Munari E; Atzori F; Montagnani I; Gobbo S; Umari P; Mosca A; Iacovelli R; Pappagallo G; Alongi F; Eccher A; Ortega C; et alii...

Toward a genome-based treatment landscape for renal cell carcinoma. in Critical reviews in oncology/hematology / Crit Rev Oncol Hematol. 2019 Oct;142:141-152. doi: 10.1016/j.critrevonc.2019.07.020. Epub 2019 Aug 2

2019
AOU Novara

Massari F; Di Nunno V; Santoni M; Gatto L; Caserta C; Morelli F; Zafarana E; Carrozza F; Mosca A; Mollica V; Iacovelli R; Sabbatini R; Porta C; Bracarda S;

Long-term Response to First-line Pazopanib Therapy in mRCC Patients: A Multicenter Italian Experience. in Anticancer research / Anticancer Res. 2018 Aug;38(8):4913-4918. doi: 10.21873/anticanres.12807.

2018
AOU Novara

Sbrana A; Biasco E; Paolieri F; Palesandro E; Caserta C; Iacovelli R; Detti B; Santini D; Mosca A; Morelli F; Fornarini G; De Giorgi U; Masini C; Galli L;

Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma. in The Journal of urology / J Urol. 2015 Jan;193(1):41-7. doi: 10.1016/j.juro.2014.07.011. Epub 2014 Jul 18.

2015
AOU Novara

Santoni M; Conti A; Porta C; Procopio G; Sternberg CN; Basso U; De Giorgi U; Bracarda S; Rizzo M; Ortega C; Massari F; Iacovelli R; Derosa L; Masini C; Milella M; Di Lorenzo G; Atzori F; Pagano M; Buti S; De Vivo R; Mosca A; Rossi M; Paglino C; Verzoni E; Cerbone L; Muzzonigro G; Falconi M; Montironi R; Burattini L; et alii...